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Background: The local treatment of lung disorders such as asthma and chronic obstructive 
pulmonary disease via pulmonary drug delivery offers many advantages over oral or   intravenous 
routes of administration. This is because direct deposition of a drug at the diseased site increases 
local drug concentrations, which improves the pulmonary receptor occupancy and reduces 
the overall dose required, therefore reducing the side effects that result from high drug doses. 
From a clinical point of view, although jet nebulizers have been used for aerosol delivery of 
water-soluble compounds and micronized suspensions, their use with hydrophobic drugs has 
been inadequate.
Aim: To evaluate the feasibility of sterically stabilized phospholipid nanomicelles (SSMs) 
loaded with beclomethasone dipropionate (BDP) as a carrier for pulmonary delivery.
Methods: 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 
5000) polymeric micelles containing BDP (BDP-SSMs) were prepared by the coprecipitation 
and reconstitution method, and the physicochemical and in vitro characteristics of BDP-SSMs 
were investigated.
Results: BDP-SSMs were successfully prepared with a content uniformity and   reproducibility 
suitable for pulmonary administration. The maximum solubility of BDP in SSMs was 
  approximately 1300 times its actual solubility. The particle size and zeta potential of BDP-SSMs 
were 19.89 ± 0.67 nm and −28.03 ± 2.05 mV , respectively. The SSMs system slowed down 
the release of BDP and all of the aerodynamic values of the aerosolized rehydrated BDP-SSMs 
were not only acceptable but indicated a significant level of deposition in the lungs.
Conclusion: The SSM system might be an effective way of improving the therapeutic index 
of nebulized, poorly soluble corticosteroids.
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Introduction
In pharmaceutical technology, many drug-releasing and drug-targeting systems 
have been developed to reduce drug degradation and/or enhance the amount of 
drug in the target area.1,2 In general, poorly water-soluble agents are usually associ-
ated with poor absorption and bioavailability.3 In addition, from a pharmacological 
point of view, hydrophobicity is beneficial for the drug–tissue relationship but 
  formulation, solubilization, and stabilization of these agents are problems that 
should be   investigated.4 Accordingly, many pharmaceutical delivery systems from 
polymeric micelles have been introduced recently due to their potential ability to 
solubilize poorly soluble drugs and to form small particle sizes (,100 nm) by which 
they evade phagocytosis.1,5
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Polymeric micelle so-called colloidal dispersions are self-
assembled core-shell nanostructures formed in an aqueous 
solution consisting of hydrophobic fragments of amphiphilic 
molecules forming the core of a micelle, which is segregated 
from the environment by hydrophilic parts of the molecules 
that form the micelle corona.6,7 Cargo space (core) formed 
from the hydrophobic segment solubilizes a variety of poorly 
soluble therapeutic and diagnostic agents. This solubiliza-
tion increases the bioavailability and circulation time after 
parenteral administration, as well as modifying the pharma-
cokinetics and biodistribution of the therapeutic agents.1,8 
The small size of the micelles permits their extravasation 
and accumulation in a variety of pathological sites such as 
tumors.4 Additionally, polymeric micelles are easily prepared 
on a large scale.8
Polymeric micelles are more stable than micelles prepared 
from conventional detergents and some amphiphilic copo-
lymers have critical micelle concentration values as low as 
10−6 M.9,10 This is especially important from a practical point 
of view, since upon dilution with a large volume of biologi-
cal fluid, micelles with a high critical micelle concentration 
value may dissociate into monomers and their content may 
precipitate.11 Moreover, polymeric micelles have high kinetic 
stability due to the presence of multiple sites capable of 
mediating the hydrophobic interaction between each other 
and/or hydrophobic drugs.12
Important types of polymeric micelle are phospholipid 
micelles, which are sterically stabilized phospholipid 
nanomicelles (SSMs) composed of polyethylene glycol 
and phospholipids (PEGylated phospholipids). PEGylated 
phospholipids are similar to the amphiphilic copolymers 
of the A-B type, except that the hydrophobic part is a 
lipid instead of a hydrophobic polymer block. Acyl chains 
of lipids form the cargo space of the polymeric micelles 
that encapsulate or solubilize a variety of poorly soluble 
therapeutic and diagnostic agents.13 Some of the most 
important PEGylated phospholipids are polyethylene 
glycol-  phosphatidylethanolamine conjugates (PEG-PE), 
such as polyethylene glycol-distearoyl phosphatidyle-
thanolamine (PEG-DSPE). The molecule consists of 
hydrophilic flexible PEG that is conjugated to two short 
hydrophobic fatty acyl groups in the polymer structure, 
leading PEG-DSPE to form stable micelles. It has also been 
reported that humans secrete phospholipase A2 (PLA2) that 
is able to degrade PEGylated phosphatidylethanolamine, 
thus making them biocompatible and biodegradable drug 
carriers.14,15   PEG-DSPE was first used to prolong the 
  circulating time of liposomes by allowing the lipid part 
to be incorporated inside the lipid bilayer while the PEG 
segment attached to the liposomal surface.16,17 The PEG 
segment at the surface has an important role in preventing 
the rapid uptake by the reticuloendothelial system, enabling 
liposomes to circulate for a longer time.13
Beclomethasone dipropionate (BDP) is a poorly water-
soluble drug (0.16 µg/mL) that is frequently used via 
inhalation in the treatment of asthma/chronic obstructive 
pulmonary disease.18 Since its biological half-life is short, 
the daily required dose is spread over 3–4 administrations 
per day.19 Recent pharmacokinetic evidence suggests that 
BDP is removed from its primary site of action, the lower 
airways, by mucociliary clearance prior to its dissolution and 
absorption, and eventually reaches the gastrointestinal tract 
due to the large particle size of the formulation.20 Therefore, 
extending its residence time with nanosized formulation in 
the lung could be favorable for maximizing its pharmacody-
namic effect and/or decreasing the risks of side effects due 
to its extra-lung absorption. Therefore, the aim of this study 
was to formulate loaded SSMs with BDP and evaluate the 
physicochemical properties and in vitro characteristics of 
this formulation.
Materials and methods
Materials
BDP was obtained from Sigma-Aldrich Chemie Gmbh 
(Steinheim, Germany); 1,2-Distearoyl-sn-glycero-3-
  phosphoethanolamine-N-methoxy-poly(ethylene glycol 
5000) (PEG5000-DSPE) was purchased from the NOF Corpo-
ration (Tokyo, Japan); high-performance liquid chromatogra-
phy (HPLC)-grade methanol and chloroform were purchased 
from Fisher Scientific (New Jersey, Canada, and Leicester, 
UK, respectively). Phosphate-buffered saline (PBS) tablets 
were purchased from Sigma-Aldrich.
Drug loading in SSMs
The BDP-SSMs were prepared using the coprecipitation rehy-
dration method previously described.21 Different molar ratios 
(0.02 to 0.16) of BDP and PEG5000-DSPE were dissolved in 
a methanol:chloroform mixture (7:3 v/v). The mixture was 
sonicated for 2 minutes using a sonicator processor (Bran-
sonic Ultrasonic 8510, Danbury, CT) and then vortexed for 
1 minute. The organic solvent was removed to form a dry film 
by vacuum rotary evaporation (Eyela N-1001S-W, Tokyo, 
Japan). Any traces of solvent remaining in this film were 
removed under a vacuum overnight.22 The dried films were 
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rehydrated with an appropriate volume of PBS and the SSMs 
were formed by gentle shaking at 40°C for 10 minutes. The 
unsolubilized BDP was removed by filtration using a 0.2 µm 
Minisart microfilter (Sartorius AG, Göttingen,   Germany). All 
of the BDP-SSM dispersions were evaluated to determine 
the maximum solubilization efficiency by particle size and 
drug content, as suggested by other researchers.22,23 Maximum 
solubility was defined as the concentration of the solubilized 
drug that produced a single-sized peak population on photon 
correlation spectroscopy (PCS), since particles that are not 
removed by filtration are sterically stabilized particles (SSPs) 
and would appear as a second signal in the PCS. A blank 
of SSMs was also prepared following the same method but 
without the model drug.
Particle size analysis
Particle size of blank- and BDP-SSMs was evaluated by 
PCS method using a Malvern Zetasizer 1000HSA (Malvern 
Instruments, Malvern, UK). The data were analyzed in terms 
of intensity-weighted distributions. Each reported experi-
mental result was the average of at least nine hydrodynamic 
diameter values obtained from an analysis of the autocorrela-
tion function accumulated for at least 300 seconds.
BDP content
Drug content measurements were performed using an 
ultraviolet-spectrophotometer (U-2000; Hitachi Ltd, Tokyo, 
Japan) at 240 nm after diluting the clear aqueous dispersion 
with methanol (1:3 v/v).
Lyophilization of SSMs
To determine the suitable concentration of PEG5000-DSPE 
for the lyophilization process, 5 mM and 10 mM aqueous 
dispersions of blank SSMs were prepared and then frozen 
at −70°C, followed by overnight lyophilization using a Lab-
conco 7753501 freeze-dry/shell-freeze system (Labconco 
Corp, Kansas City, MO). The lyophilized cakes were also 
examined visually and the particle size and polydispersity 
index (PI) was determined. The BDP-SSMs with a maximum 
BDP solubility were lyophilized accordingly for long-term 
storage.24
Zeta potential
The measurement of zeta potential is a good means of 
evaluating the stability and the state of polymeric micelle 
surfaces and detecting any modification after freeze drying. 
Approximately 0.5 mL of each of the different formulations 
was analyzed using a ZEECOM ZC-3000 Zeta Potential 
Analyzer (Symphotic TII Corporation, Camarillo, CA).
Determination of entrapment efficiency, 
yield, and drug-loading percentages
The reconstituted BDP-SSMs were analyzed in terms of 
entrapment efficiency (%EE), yield percentage (%Y), 
and drug-loading percentage (%DL) using the following 
equations:25
  %EE = 
 

  ×
a
b
100   (1)
where (a) is the concentration of drug loaded in the SSMs 
(µg/mL) and (b) is the amount of drug used in the SSM 
preparation (µg/mL).
%Y =
Weightof thenanoparticles
Weightof thefeedingpolymeranddrug g

 

  ×100
 
(2)
%DL =
Weightof thedrug innanoparticles
Weightof thenanoparticles s

 

  ×100
 
(3)
Fourier transform infrared (FTIR) 
spectroscopy characterization
FTIR is a good means of evaluating the possible chemical 
interaction between BDP and PEG5000-DSPE. The FTIR 
spectra were obtained using an infrared spectrophotometer 
(Nexus equipped with OMNIC software [v 6.1]; Thermo 
Nicolet Corp, Madison, WI). The samples, which consisted 
of approximately 1 to 2 mg of BDP, a physical mixture of 
BDP and the PEG5000-DSPE, lyophilized loaded SSMs of 
BDP, and PEG5000-DSPE and potassium bromide (KBr) 
powder, were triturated in an agate mortar with a pestle at a 
ratio of approximately 1:100 or 2:100 (sample:KBr, [w/w]) 
and compressed by a compaction force of 16 tons cm−1 and a 
holding time of 2 minutes to form a disc. The infrared   spectra 
were collected within the range of 400–4000 cm−1.
Differential scanning calorimetry 
characterization
To evaluate the physical state of BDP in SSMs, thermal 
analysis of the BDP-SSMs, the corticosteroid drug (BDP), the 
PEGylated polymer (PEG5000-DSPE), and the physical mixture 
of the corticosteroid drug and the PEGylated polymer was per-
formed using a Pyris 6 differential scanning calorimeter (DSC) 
(PerkinElmer, Waltham, MA) as previously described.26
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Transmission electron microscopy (TEM) 
characterization
TEM is one of the common methods used to examine 
  nanoscopic polymeric micelles. Morphological examinations 
of the rehydrated BDP-SSMs were conducted using a TEMx 
transmission electron microscope (CM12 with Docu version 
3.2 Image analysis; Philips, Amsterdam, The Netherlands) 
as previously described. 26
Dissolution study
To determine the sink condition, the solubility of BDP in 
PBS was measured by placing an excess amount of BDP 
(300 mg) in 5 mL PBS (pH 7.4) in a dialysis bag (Spectra/pro, 
molecular weight cut-off 10,000 KD; Spectrum Chemicals 
and Laboratory Products, New Brunswick, NJ) placed in 
a 100 mL PBS Pyrex® bottle and shaken horizontally at 
100 rpm in a thermostatic water bath (WB 22; Memmert 
GmbH and Co KG, Büchenbach, Germany) at 37°C ± 0.5°C. 
Samples of the drug solution were withdrawn from the bottle 
(200 µL, after 30 hours) and analyzed by a validated HPLC 
method as previously described.27 Due to the low solubility of 
BDP, Tween® 80 (R&M chemicals, Essex, UK) at a concentra-
tion of 0.1% (v/v) was added to the dissolution medium to 
increase the drug solubility and to ensure the sink condition. 
The resulting equilibrium drug concentration was used to 
calculate the saturated solubility drug concentration.28
For the dissolution study, a dialysis bag method was 
used as previously described, with minor modification.26 
A known amount of rehydrated BDP-SSMs or BDP powder 
(containing the equivalent amount of BDP [200 µg] required 
for the sink condition) was diluted in 5 mL of PBS (pH 7.4) 
and transferred into a dialysis bag. At predetermined time 
intervals, 200 µL of sample was withdrawn from the bottle 
and analyzed by a validated HPLC method, as described 
previously.27 The kinetics of drug release were examined 
using the previously described add-in DDSolver program.29 
Different mathematical kinetic models (zero order, first order, 
Higuchi, Hixson–Crowell, and Baker–Lonsdale) were used to 
determine the drug-release kinetics. The criteria for selecting 
the most appropriate model were based on the goodness of 
fit (adjusted coefficient of determination, R2
adjusted) and the 
Akaike information criterion.30
in vitro pulmonary deposition
Aerodynamic characterization was investigated using a Model 
170 Next Generation ImpactorTM (NGITM; Copley Scientific 
Ltd, Nottingham, UK) connected to a vacuum pump (HCP4) 
and Pari LC nebulizer (connected to an air-jet compressor Pari 
Master type 84G73; Munich, Germany). A flow meter (DFM2; 
Copley Scientific Ltd, Nottingham, UK) was used to calibrate 
the airflow through the NGI. Two milliliters of an aqueous 
preparation containing 0.5 mg of rehydrated BDP-SSMs was 
nebulized for 15 minutes at a room temperature of 28°C and a 
relative humidity of 65%. The flow rate of 60 L/min simulated 
the mean peak inspiratory flow rate of adult asthmatic patients.27 
The effective cut-off diameters for the impactor at a flow rate 
of 60 L/min were: 8.06 µm (stage 1), 4.46 µm (stage 2), 
2.82 µm (stage 3), 1.66 µm (stage 4), 0.94 µm (stage 5), 
0.55 µm (stage 6), and 0.34 µm (stage 7). Each stage of the 
NGI, the induction port, and the inhaler device were rinsed 
with 10 mL of the respective HPLC mobile phase and col-
lected for quantitative analysis by HPLC.27
The mass median aerodynamic diameter (MMAD) and 
geometric standard deviation (GSD) were calculated after 
plotting the cumulative amount of drug under size deposited 
in each stage of the cascade impactor versus their correspond-
ing aerodynamic diameter as specified by the cascade impac-
tor using log-probability paper.31 On this graph, the MMAD 
of the aerosolized particles is the particle size at which the 
line crosses the 50% mark (MMAD [µm] = D50%).
From a log-normal distribution that is normal with respect 
to aerodynamic diameter,31 the GSD becomes:
  GSD
undersize
undersize
=

 

 
84 1
15 9
.%
.%
  (4)
The emitted dose (ED) was determined as the percentage 
of total amount of drug available for nebulization:27,32
ED =
Amount of drug recoveredi nt he cascade impactor
Amount of drug ini itially loaded in thed evice

 

 
× 100%  (5)
The fine particle fraction (FPF) was calculated as the total 
amount of drug deposited on stage 2 or 3 to filter:27,32,33
FPF =
Amount of drug recovered froms tage 2o r3to filter
Amount of drug i initially loaded in thed evice

 

 
× 100%
 
(6)
Stability study of SSMs
Short-term stability of drug-loaded SSMs
Aqueous dispersions of the final formulations of 
  BDP-SSMs were kept at an ambient temperature of 
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28°C ± 3°C with 70% ± 10% relative humidity for 
3 months.4 After a   predetermined time interval, the 
  dispersions were filtered through a 0.2 µm Minisart 
microfilter, and the clear aqueous solution was diluted 
with methanol (drug-loaded SSMs: methanol, 1: 3 [v/v]). 
Drug-content analysis was performed using an ultraviolet-
spectrophotometer method.
Long-term stability of drug-loaded SSMs
To assess the storage stability (long-term stability), 
  lyophilized BDP-SSMs were stored at an ambient   temperature 
of 28°C ± 3°C, or at 4°C (refrigerator) in a desiccator or at 
−20°C for 1 year. After a predetermined time interval, the 
lyophilized BDP-SSMs were rehydrated with distilled water 
(DW) and the drug content and Zave were examined.
The percentage of drug remaining was calculated as 
below:
  %% remain= 
 

  ×
b
a
100   (7)
where a is the initial drug concentration at zero time and b 
is the drug concentration after a specified time.
Results and discussion
Drug loading
Several techniques have been reported for the preparation 
of drug-loaded polymeric micelles. Those techniques can 
be divided to three major categories: (1) the coprecipitation 
and reconstitution method, (2) the dissolution method, and 
(3) the dialysis method. In each particular case, the choice 
of the method is usually determined by the extent of the 
stability of the model drug in organic or aqueous media 
and the extent of miscibility of the organic solvent with 
aqueous media.8
In direct dissolution, block copolymer is simply dissolved 
in an aqueous medium at normal or elevated temperature 
and the model drug, such as peptides, is added to form the 
peptides-SSMs. This method is useful for active model 
drugs, which are unstable in organic solvent but soluble in 
aqueous media.24,34 In the dialysis method, the drug of inter-
est is dissolved in a water-miscible organic solvent (such 
as dimethyl sulfoxide) and is added to the dried film of the 
PEG-PE, and drug-loaded micelles are formed upon the 
removal of the organic solvent by dialysis with water. This 
method has a greater chance of drug loss during dialysis in 
the encapsulation process and is more difficult in scale-up 
production; in addition, the choice of organic solvent affects 
the particle size and uniformity of the micelles formed.35,36 
Other researchers have presented distinctions between 
PEG-b-poly(ε-caprolactone) polymeric micelles prepared 
using different methods.36 They found that the dialysis 
preparation method did not provide adequate size control, 
whereas stable assemblies with unimodal size distributions 
were obtained using the coprecipitation and reconstitution 
preparation method.
The simplest and most convenient technique for 
the preparation of drug-loaded PEG-DSPE micelles 
is the coprecipitation and reconstitution method. This 
method is utilized for the preparation of many polymeric 
micelles because of its simplicity and reproducibility. 
Many examples were found in the literature utilizing this 
method.37–40 Herein, BDP was successfully incorporated 
into SSMs of PEG5000-DSPE by the coprecipitation and 
reconstitution method.
Physicochemical properties of BDP-SSMs
Maximum solubilization of BDP
The maximum solubility of BDP in SSMs was assessed 
with eight different BDP concentrations ranging from 52.1 
to 416.8 µg/mL in 5 mM PEG5000-DSPE. All samples # 
209.65 ± 7.74 µg/mL (0.08 drug:PEGylated polymer molar 
ratio) had a single uniform size distribution; above this con-
centration a second peak was observed and this represents 
the SSPs (Figure 1).
The maximum solubility value of BDP in PEG5000-DSPE 
was at least 1300 times greater than the BDP water solubil-
ity (0.16 µg/mL) as previously reported, which indicates the 
suitability of the carrier to solubilize BDP.18 The SSPs were 
most likely stabilized by the PEG-DSPE and formed aggre-
gates in order to maximize the hydrophobic interactions and 
hydrogen bonding network with water.22,23 A similar finding 
has been reported by Paivarinta et al, who found that BDP 
formed crystals in dipalmitoylphosphatidylcholine multila-
mellar liposomes which affected the determined solubilized 
concentration.41
Unlike the SSMs at maximum solubility, SSPs affected 
the stability of the aqueous dispersion of SSMs because they 
allowed crystallized nuclei to grow and resulted in a turbid 
solution after 24 hours at 4°C.42 This temperature was used 
as an intermediate temperature between freezing and the 
ambient temperatures, since efficiently solubilized drug in 
PEGylated polymer formulations should be stable prior to 
freeze-drying and also after reconstitution.39
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PEgylated polymer concentration for lyophilization 
of SSMs
Both 5 and 10 mM of the PEGylated polymer were 
  examined. The results showed that the freeze-dried blank-
SSM samples had freeze-dried cakes with a fluffy physical 
appearance (Figure 2A). All freeze-dried samples dissolved 
upon reconstitution with DW to form clear, colorless 
  solutions. To assess the effect of sample volume, 1 and 
0.5 mL of the blank samples were lyophilized and there 
were no visual texture differences pronounced for the 
freeze-dried cakes (Figure 2B).
In addition, there was a decrease in SSM particle sizes 
with an increase in the PEGylated polymer concentration, 
even though it was not significant (P . 0.05) with narrow 
PI (Table 1).
Micelle–micelle interactions could occur at a PEGylated 
polymer concentration of 10 mM due to the closeness of the 
neighboring micelles; folding of the PEG polymer would 
take place and result in the formation of a constrained 
  “mushroom” conformation. As a result, smaller particle 
sizes were obtained, even though this result can be insig-
nificant. At a lower PEGylated polymer concentration of 
5 mM, the greater distance between SSMs would allow the 
PEG palisade to form a relaxed “brush” conformation and, 
hence, larger particle sizes (aggregations) were measured.34 
Particle surface charge decreased significantly with increas-
ing PEGylated polymer concentration (P , 0.05). Yang et al 
reported that the particle size and surface charge of SSMs 
depended on the surface density of the PEG block on the 
lipid core and the concentration of the PEGylated polymers, 
which was similar to our finding.43 Thus, PEGylated polymer 
could be lyophilized successfully at 5 mM since the hydro-
philic PEG polymer in the outer surface (corona) acted as a 
cryoprotectant and lyoprotectant.23
Particle size analysis and zeta potential of BDP-SSMs
The hydrodynamic particle size, zeta potential, and PI values 
of BDP-SSMs (at maximum solubilization) and blank SSMs 
differed insignificantly (Table 1), which indicated that the 
PEG5000-DSPE copolymer at a concentration of 5 mM was 
suitable for lyophilization without further addition of any 
cryoprotectant or lyoprotectant agents. The lyophilized BDP-
SSMs were white in color, fluffy and cotton-like in appear-
ance, and easily dissolved in DW (Figure 2C). These results 
indicated that the model drug had no effect on the formation 
characteristics of SSMs even after the freeze-drying process. 
The negative surface charge confirmed the stability potential 
of the SSM formulations.44 Typically, PEG is conjugated to 
distearoyl phosphatidylethanolamine (DSPE) via a carbamate 
linkage that results in a net negative charge on the phosphate 
moiety.38,45 Both particle size and zeta potential values of the 
BDP-SSMs gave an advantage to the SSM formulations as a 
pulmonary delivery system. It has been reported that particles 
of ,260 nm can escape phagocytosis by macrophages, and 
that negatively charged particles are arrested in the lungs 
more efficiently than positively charged molecules.46,47 These 
results make the SSM formulations promising carriers for 
pulmonary delivery.
BDP: PEGylated polymer molar ratio
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Figure 1 Effect of the BDP: PEgylated polymer molar ratio on the solubilization of BDP; PEgylated polymer molar concentration kept at 5 mM.
Note: Lined bars indicate second population signal in PCS.
Abbreviations: BDP, beclomethasone dipropionate; PCS, photon correlation spectroscopy; PEg, polyethylene glycol.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
34
Sahib et alDrug Design, Development and Therapy 2012:6
Figure 2 Freeze-dried cakes of SSMs. (A) Blank SSMs at 5 mM and 10 mM (1 mL); (B) blank SSMs at 5 mM and 10 mM (0.5 mL); (C) BDP-SSMs.
Abbreviations: BDP-SSMs, sterically stabilized phospholipid nanomicelles containing beclomethasone dipropionate; SSMs, sterically stabilized phospholipid nanomicelles.
Entrapment efficiency, drug loading, and yield 
percentages of the lyophilized drug-loaded SSMs
According to the spectrophotometric results and   particle 
size distribution, all BDP molecules were   incorporated into 
the SSMs after lyophilization, which was   supported by the 
  insignificant difference found in %EE     pre- (100.60 ± 3.71) and 
post-lyophilization (100.87 ± 3.59) (P . 0.05) with no   formation 
of SSPs, as identified by PCS. In   addition, a high %Y 
(95.11 ± 0.38) and considerable %DL (0.72 ± 0.03) of the BDP-
SSM   formulations were obtained.
Differential scanning calorimetry
DSC thermograms of the various samples are shown in 
Figure 3.
BDP melted with decomposition at approximately 
210°C ± 0.01°C. The peak for PEG5000-DSPE  was 
59.91°C ± 0.04°C. The peaks of the physical mixtures of 
BDP and PEG5000-DSPE were approximately 201°C ± 1.52°C 
and 59.64°C ± 0.57°C, respectively, with a sharp decrease 
in the peak intensity for BDP. The lyophilized BDP-SSMs 
showed only one peak at approximately 58°C for PEG5000-
DSPE SSMs with no BDP peak.
These results indicated that the physical mixing of the 
drug and PEGylated polymer did not affect the block copo-
lymer structure. In contrast, BDP-SSMs caused a slight but 
significant downward shift of the endothermic peak of the 
PEGylated polymer, which indicated that there were physical 
interactions between BDP and the PEGylated polymer. The 
interactions also suggested that BDP might be molecularly 
dispersed in the block copolymer matrix. The disappearance 
of the endothermic peak confirms that BDP changed from 
the crystalline form to the amorphous state.48 Similar results 
have been reported by other researchers.49,50
The disappearance of the endothermic peak correspond-
ing to the melting of BDP at low drug concentrations in the 
BDP-SSMs was due to their complete miscibility in the 
molten PEGylated polymer. However, at higher drug ratios 
(physical mixture), only a partial miscibility was reached 
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Figure 3 DSC thermograms of BDP, PEg5000-DSPE, physical mixture and BDP-SSMs.
Abbreviations:  BDP-SSMs,  sterically  stabilized  phospholipid  nanomicelles 
containing  beclomethasone  dipropionate;  DSC,  differential  scanning  calorimeter; 
PEg5000-DSPE,  1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly 
(ethylene glycol 5000).
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and the drug only began to melt at 198°C ± 2.00°C. Similar 
results have been reported in a study of interaction between 
PEG6000 and oxazepam.51
FTir
BDP has conjugated and nonconjugated C=O stretching 
bands. Thus, the bands at 1730 and 1654 cm−1 in the BDP 
spectrum (Figure 4) corresponded to the nonconjugated 
acetyl C=O stretch and the conjugated stretch bands, 
respectively. In addition, there was an (OH) vibrational 
band at 3271 cm−1. Another important band (C=C stretch-
ing band) for the structure identification of BDP was found 
at 1614 cm−1.52 The BDP FTIR spectrum showed a C=O 
stretching band for an ester at 1754 cm−1.
The BDP physical mixture with PEG5000-DSPE exhib-
ited similar spectra. However, the lyophilized BDP-SSMs 
exhibited a shift in conjugated C=O stretching band from 
1654 to 1660 cm−1. This shift was caused by an altered 
environment of the interatomic C=O bonds from the solva-
tion process in the hydrophobic portion of the PEGylated 
polymer. The formation of intermolecular hydrogen bonds 
between the OH group of BDP and the C=O groups of 
PEGylated polymer could be a possible explanation for this 
shift. In addition, the (OH) vibration band of BDP-SSMs 
was shifted, from 3271 to 3288 cm−1. The C=O stretching 
band of the ester was also largely decreased in intensity. The 
C=C stretching band was changed to a broader peak without 
shifting (1614 cm−1). Hyvönen et al reported similar findings 
where all bands of BDP (OH, C=O, and C=C) shifted to 
higher wave numbers.52
No pronounced interactions could be identified 
between BDP and the PEGylated polymer because no 
Table 1 Particle size, polydispersity index (Pi) and zeta potential of SSMs before and after freeze-drying
PEGylated polymer  
and/or BDP-SSMs
Concentrations (mM) Particle size (nm) PI Zeta potential (mV)
Before FD After FD Before FD After FD Before FD After FD
PEg5000-DSPE 5 20.30 ± 1.31 20.31 ± 1.32 0.20 ± 0.02 0.21 ± 0.02 −28.70 ± 2.21 −27.18 ± 2.50
10 17.33 ± 2.08 18.55 ± 2.25 0.20 ± 0.02 0.21 ± 0.01 −45.51 ± 2.35 −45.69 ± 1.63
BDP: PEg5000-DSPE 0.4:5 (Drug: PEgylated  
polymer concentration)
19.99 ± 0.99 19.89 ± 0.67 0.21 ± 0.02 0.22 ± 0.02 −27.70 ± 2.25 −28.03 ± 2.05
Abbreviations: BDP, beclomethasone dipropionate; BDP-SSMs, sterically stabilized phospholipid nanomicelles containing beclomethasone dipropionate; FD, freeze drying; 
PEg, polyethylene glycol; PEg5000-DSPE, 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 5000); SSMs, sterically stabilized phospholipid 
nanomicelles.
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significant change or disappearance was evident in the 
important areas of the spectrum band (conjugated and non-
conjugated C=O and C=C stretching bands), which would 
indicate that the BDP molecules were in an amorphous 
state. This result was confirmed by differential scanning 
calorimetry analysis.
Morphological examination
Morphological observation of the TEM of BDP-SSMs 
revealed spherical nanoparticles with bright and dark areas 
and a core-shell multivesicular appearance with a mean 
particle size of 104.08 ± 27.30 nm (Figure 5). The mean 
diameters of the blank-SSMs were 100.46 ± 33.24 nm. These 
measurements significantly differed from the PCS results. 
This difference was caused by the tendency of the particles 
to aggregate as a result of drying the samples, which has also 
been reported by other researchers.53
in vitro dissolution of BDP-SSMs
The solubility result of BDP in PBS showed a very 
low value (0.15 ± 0.04 µg/mL) but the solubility of 
BDP was markedly increased when Tween 80 (0.1% 
v/v) was added to the dissolution medium and reached 
14.34 ± 1.28 µg/mL. The addition of a low concentration 
of surfactants to the dissolution medium ensured the sink 
condition for some poorly water-soluble compounds.54–57 
The aqueous solubility of BDP found in this study was 
in good agreement with the previously reported result of 
0.16 µg/mL.18 A sink condition is achieved if the final 
concentration of the drug in the dissolution medium is 
,20% of the saturation solubility of the drug.58 The final 
concentrations of BDP after the complete release in PBS 
were found to be ,2.87 µg/mL and were in compliance 
with the sink conditions.
Comparison of the dissolution release profiles of 
  BDP-SSMs with BDP powder at the end of the first 
6 hours revealed that .90% of BDP powder was released, 
while ,41% of BDP was released from BDP-SSMs, with 
completion of release within 3 days (Figure 6).
The most appropriate drug-release model was selected 
based on its highest adjusted coefficient of determination 
(R2
adjusted) value and lowest Akaike information criterion. 
It was found that BDP-SSMs most closely followed the 
Figure  5  Morphological  examinations  of  BDP-SSMs  by  transmission  electron 
microscopy.
Note: Scale bar = 2 µm and 50 nm.
Abbreviation: BDP-SSMs, sterically stabilized phospholipid nanomicelles containing 
beclomethasone dipropionate.
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Figure 6 Drug-release profiles of BDP-SSMs and BDP reference powder.
Abbreviations: BDP, beclomethasone dipropionate; BDP-SSMs, sterically stabilized phospholipid nanomicelles containing beclomethasone dipropionate.
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  Baker–Lonsdale model (P , 0.05) and further supported the 
postulation that the release of BDP from SSMs is more consis-
tent with a diffusion mechanism (Higuchi model) (P , 0.05) 
(Table 2) while BDP powder followed the zero-order kinetic.
Aerodynamic characterization  
of BDP-SSMs
The distribution of the BDP in the nebulizer, the induction 
port (throat), and the seven stages of the NGI are clearly 
demonstrated in Figure 7.
The MMAD, GSD,%ED, and FPF<2.8 or 4.8  were 
2.83 ± 0.02 µm, 2.31 ± 0.08 µm, 59.58% ± 0.85%, and 
36.84% ± 0.4% or 52.56% ± 0.72%, respectively. These 
results were significantly superior than the results for the 
Clenil® (a BDP suspension for nebulization, not approved 
by the US Food and Drug Administration) from Chiesi, 
Italy, as the MMAD, FPF<3, FPF<5 were 7.5 µm, 7%, and 
23% respectively.59 These significant differences were due 
to shape and particle size differences. Vaghi et al59 found 
that Clenil contained needle-shaped particles up to 10 µm 
long, while in our study the BDP-SSMs were spherical with 
a diameter of 14.60 ± 1.11 nm on PCS and 100.46 ± 33.24 nm 
on TEM. The nebulized suspension will therefore generate 
larger aerosol droplets (ie, larger MMAD values) contain-
ing a small number of suspension particles, whereas the 
aerosolized SSM droplets are smaller (with lower MMAD 
values) and contain many thousands of nanoparticles.48 The 
effect of particle size on the aerodynamic characterization 
was also reported by other researchers.48,60,61 In addition, the 
effect of the formulation must also be considered. The pres-
ence of PEG on the outer layer of the polymeric micelles, 
which induced a repulsive steric interaction between the 
particles that could effectively decrease the overall adhesive 
forces, allowed a more efficient aerosolization, stabilizing 
the colloidal suspension in the air.61,62 These results support 
the potential of BDP-SSMs made from PEG5000-DSPE to be 
Table 2 Kinetic drug-release values of different BDP formulations
Parameters Adjusted coefficient  
of determination (R2
adjusted)
The Akaike information  
criterion
Release rate constant
BDP-SSMs BDP powder BDP-SSMs BDP powder BDP-SSMs BDP powder
Zero-order kinetic 0.59 ± 0.06 0.98 ± 0.01 93.38 ± 2.22 35.97 ± 1.10 / 17.02 ± 0.41
First-order kinetic 0.89 ± 0.03 0.94 ± 0.01 78.28 ± 2.56 43.28 ± 2.31 / /
higuchi kinetic 0.96 ± 0.01 0.86 ± 0.02 67.84 ± 3.72 49.40 ± 1.57 12.30 ± 0.52 /
Baker–Lonsdale model kinetic 0.98 ± 0.01 / 60.39 ± 1.99 / 0.004 ± 0.00 /
hixson–Crowell model kinetic 0.85 ± 0.03 / 82.07 ± 1.92 / / /
Abbreviations: BDP, beclomethasone dipropionate; BDP-SSMs, sterically stabilized phospholipid nanomicelles containing beclomethasone dipropionate.
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useful drug carriers in the treatment of pulmonary-related 
diseases.
Stability of loaded SSMs
Temperature is an important factor that affects micellar 
  structure. Micelles are formed at a specific temperature, which is 
known as the critical micellization temperature (CMT). Values 
between 25°C and 40°C are identified as the CMT for most 
block   copolymers. If micelles are refrigerated for a long period 
of time, the temperature drops to a value lower than the CMT 
and, as such, polymeric micelles would lose their structure and 
the solubilized drug would be precipitated out.63 For this reason, 
a short-term stability test was performed at the ambient tempera-
ture of 28°C ± 3°C with 70% ± 10% relative humidity.
There were insignificant differences in the drug 
  concentration (or drug remaining) after a storage period of 
1 month. However, after a storage period of 2 or 3 months, 
the drug concentration (or drug remaining) decreased 
  significantly (P , 0.05) (Figure 8). These results indicated 
that the solubilized corticosteroid drug maintained sufficient 
stability as drug-loaded SSMs for a period of 1 month.
In general, the stability of SSMs depended on the storage 
time as well as the degradation tendency of PEGylated micellar 
structure. As specified by the manufacturer, the commercial 
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Figure 8 Short-term stability results of aqueous dispersion of BDP-SSMs at 28°C ± 3°C and 70% ± 10% relative humidity.
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Concentration
250
200
150
100
100
80
60
40
20 50
0 0
B
D
P
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(
µ
g
/
m
L
)
%
 
r
e
m
a
i
n
i
n
g
Zero time Freezer (−20°C) Refrigerator (4°C) Ambient temperature
(28°C ± 3°C)
% remaining
Figure 9 Long-term stability results of lyophilized BDP-SSMs at different storage temperatures for 1 year.
Abbreviation: BDP-SSMs, sterically stabilized phospholipid nanomicelles containing beclomethasone dipropionate.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
39
Pulmonary nanocarrier of beclomethasone dipropionateDrug Design, Development and Therapy 2012:6
PEG-DSPE block copolymers are in powder form and must 
be kept at or below −20°C. Thus, keeping these polymeric 
micelles at ambient temperature (28°C ± 3°C) in aqueous 
solutions was not appropriate with respect to storage stability. 
Our study confirmed that PEG-DSPE block copolymers were 
more stable in lyophilized form. These results are in agreement 
with other reports. Sezgin et al reported that the stability of 
the polymeric micelles of PEG-DSPE and meso-tetraphenyl 
porphine (an anticancer agent) decreased by approximately 
13% after 3 months at ambient temperature.4
For the long-term stability study, lyophilized formulations 
were kept at −20°C, 4°C, and 28°C. Even though PEG-DSPE 
is more stable in its lyophilized form, the storage temperature 
has a great effect on its final solubilization efficiency. The 
concentrations of the BDP at time zero and after 12 months 
at different storage temperatures are shown in Figure 9.
There were insignificant differences between the con-
centrations of BDP (or drug remaining) at time zero and 
after storage for 12 months at −20°C and 4°C (P . 0.05). 
However, there were significant differences between the 
concentrations of BDP (or drug remaining) at time zero and 
after storage for 12 months at the ambient temperature of 
28°C (P , 0.05).
In addition, there were significant differences in the 
Zave and PI values for the BDP-SSMs when stored at 28°C 
(Table 3).
These results corroborated the previous concentration 
analysis findings that a change in particle size of the SSMs 
was more prominent when stored at 28°C than at −20°C 
or 4°C. Results of the stability studies indicated that when 
stored at −20°C and 4°C the lyophilized BDP-SSMs were 
sufficiently stable for at least 1 year after preparation.
Conclusion
BDP-SSMs were successfully prepared by the coprecipitation 
and reconstitution method. The maximum solubility value 
of BDP in PEG5000-DSPE was at least 1300 times greater 
than the BDP water solubility. Maximum solubility should 
only be measured when the drug-loaded SSMs exhibited a 
unimodel distribution in PCS. SSPs affected the stability 
of the SSMs because they provided nuclei for the forma-
tion of aggregates, which disrupted the micellar structures. 
BDP was found to be amorphous by differential scanning 
  calorimetry, and had no chemical interaction with PEGylated 
polymer according to FTIR results. BDP-SSMs exhibited 
prolonged dissolution behavior compared with the reference 
powder. BDP-SSMs successfully aerosolized with significant 
  aerodynamic characterization values. The physicochemical 
and in vitro evaluation results showed SSM formulations of 
BDP to be a promising pulmonary delivery system.
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